An Osseoanchored Percutaneous Prosthesis Study Evaluating Stable Neural Signal Transmission in Subjects With Transhumeral Amputations

• ClinicalTrials.gov Identifier: NCT03957226
• Recruitment Status: Enrolling by invitation
• First Posted: May 21, 2019
• Last Update Posted: May 13, 2021
• Sponsor: University of Michigan
• Collaborator: University of California, San Francisco
• Information provided by (Responsible Party): Paul Cederna, University of Michigan

Study Description

Brief Summary:

This early feasibility study proposes to evaluate use of the electronic-Osseoanchored Prostheses for the Rehabilitation of Amputees (e-OPRA) device, a transhumeral implant system for direct skeletal anchorage of amputation prostheses, with a test prosthesis. The e-OPRA System is being investigated to better understand the ability to improve the functionality of the prosthesis and enhance the sense of embodiment of the prosthesis itself. This will be a 10 subject Early Feasibility Study in which the primary objective is to capture preliminary safety and effectiveness information on the implanted e-OPRA system. With the addition of electrodes to the muscle segments, this biological interface allows for both the extraction of fine motor control signals from the nerve fascicles and the generation of sensory percepts via electrical stimulation of the muscles. In addition, electrodes placed on muscles within the residuum with native vascularization and innervation also allow the extraction of critical motor control signals and the generation of sensory feedback through muscle stimulation. The electrical activity recorded from these muscle segments (called electromyography or EMG) is specific to certain movements and can be used to determine precisely how a person wants to move their arm and hand. Use of the e-OPRA device with the well-documented neuro-electronic capabilities of EMG control systems provides an alternative to traditional socket prostheses by establishing a direct, loadbearing link between the patient's skeleton and prosthesis.

Condition or disease	Intervention/treatment	Phase
Amputation Neuroma; Amputation; Prosthesis User	Device: e-OPRA (electronic-Osseoanchored Prosthese for the Rehabilitation of Amputees)	Not Applicable

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 10 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Device Feasibility
• Official Title: An Osseoanchored Percutaneous Prosthesis Study Evaluating Stable Neural Signal Transmission in Subjects With Transhumeral Amputations
• Actual Study Start Date: January 30, 2020
• Estimated Primary Completion Date: March 2023
• Estimated Study Completion Date: March 2024

Arms and Interventions

Arm

Intervention/treatment

Experimental: Trasnhumeral e-OPRA Implant; This arm includes patients with transhumeral amputation that will receive the e-OPRA implant system.

Device: e-OPRA (electronic-Osseoanchored Prosthese for the Rehabilitation of Amputees); The e-OPRA is an implant system that provides an alternative to traditional socket prostheses by establishing a direct, load-bearing link between the patient's skeleton and a prosthesis for transhumeral amputees. The anchorage element of the system is implanted directly into the bone while the electrodes that provide control signals for the prosthesis are implanted into muscle grafts on the transhumeral amputation.

Outcome Measures

Primary Outcome Measures :

1. Change in Electrical signal quality between implanted electrodes and test prosthesis [ Time Frame: Baseline, 24 months ]
   Efficacy will be evaluated by signal-to-noise ratio during maximum voluntary contraction of at least two independent myoelectric signals.
2. Adverse Events [ Time Frame: Baseline ]
   Safety will be evaluated by assessing the adverse event type, incidence, timing, severity, treatment, outcome, and relationship to the device.
3. Adverse Events [ Time Frame: 3 Months Post-Op ]
   Safety will be evaluated by assessing the adverse event type, incidence, timing, severity, treatment, outcome, and relationship to the device.
4. Adverse Events [ Time Frame: 6 Months Post-Op ]
   Safety will be evaluated by assessing the adverse event type, incidence, timing, severity, treatment, outcome, and relationship to the device.
5. Adverse Events [ Time Frame: 9 Months Post-Op ]
   Safety will be evaluated by assessing the adverse event type, incidence, timing, severity, treatment, outcome, and relationship to the device.
6. Adverse Events [ Time Frame: 12 Months Post-Op ]
   Safety will be evaluated by assessing the adverse event type, incidence, timing, severity, treatment, outcome, and relationship to the device.
7. Adverse Events [ Time Frame: 15 Months Post-Op ]
   Safety will be evaluated by assessing the adverse event type, incidence, timing, severity, treatment, outcome, and relationship to the device.
8. Adverse Events [ Time Frame: 18 Months Post-Op ]
   Safety will be evaluated by assessing the adverse event type, incidence, timing, severity, treatment, outcome, and relationship to the device.
9. Adverse Events [ Time Frame: 21 Months Post-Op ]
   Safety will be evaluated by assessing the adverse event type, incidence, timing, severity, treatment, outcome, and relationship to the device.
10. Adverse Events [ Time Frame: 24 Months Post-Op ]
    Safety will be evaluated by assessing the adverse event type, incidence, timing, severity, treatment, outcome, and relationship to the device.

Secondary Outcome Measures :

1. Number of Subjects with 2 or more Degrees of Freedom [ Time Frame: Baseline, 24 months ]
   The number of subjects achieving 2 or more degrees of freedom summarized using frequency and percentage
2. Change in Pain Level as measured by SF-36 [ Time Frame: Baseline, 24 months ]
   Change in Pain Level as measured by SF-36 survey Pain will be assessed using the SF-36 survey instrument, to be filled out by the participant before and after each surgical procedure performed and at a minimum of once per month while electrodes remain implanted. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability.
3. Change in Pain Level as measured by LANSS surveys [ Time Frame: Baseline, 24 months ]
   Change in Pain Level as measured by LANSS survey Pain will be assessed using the LANSS survey instrument, to be filled out by the participant before and after each surgical procedure performed and at a minimum of once per month while electrodes remain implanted. A score greater than 12 (From 0 to 15) indicates neuropathic pain.
4. Change in prosthetic functionality and performance as measured by the SHAP (Southhampton Hand Assessment Procedure) [ Time Frame: Baseline, 24 months ]
   Measured by the participant performing the SHAP at each experimental visit. A higher score indicates increased upper limb functionality.
5. Change in prosthetic functionality and performance as measured by the AM-ULA (Activities Measure for Upper Limb Amputees) [ Time Frame: Baseline, 24 months ]
   Measured by the participant performing the AM-ULA at each experimental visit. A higher score indicates increased upper limb functionality.
6. Change in prosthetic functionality and performance as measured by the UEFT (Upper Extremity Function Test) [ Time Frame: Baseline, 24 months ]
   Measured by the participant performing the UEFT at each experimental visit. A higher score indicates increased upper limb functionality.
7. Change in Pain Level as measured by PROMIS (Patient Reported Outcomes Measurement Information System) Questionnaire [ Time Frame: Baseline, 24 months ]
   Change in Pain Level as measured by LANSS survey Pain will be assessed using the LANSS survey instrument, to be filled out by the participant before surgery and at each experimental visit. The Numeric Rating Scale measures (adult, pediatric, parent proxy) each consist of a single item rating pain on average over the past 7 days from 0 (no pain) to 10 (worst pain you can think of). The items are not calibrated and do not produce a T-score. Instead, raw response scores (0 to 10) should be used for analyses.
8. Change in prosthetic functionality as measured by the DASH Questionnaire [ Time Frame: Baseline, 24 months ]
   Measured by the participant filling out the DASH questionnaire before surgery and at each experimental visit every 3 months. A score closer to 1 indicates higher functionality. The DASH Outcome Measure is scored in two components: the disability/symptom section (30 items, scored 1-5) and the optional high performance Sport/Music or Work section (4 items, scored 1-5). The raw is transformed to a zero-to-100 scale, with an average score closer to 100 meaning higher disability (unable to perform tasks).
9. Change in Pain Level as measured by DVPRS (Defense and Veterans Pain Rating Scale) [ Time Frame: Baseline, 24 months ]
   Measured by the participant assigning a number 1-10 of their pain while viewing the DVPRS. A score close to of 0 indicates zero pain, and a score of 10 indicates maximum pain as bad is it can be.
10. Change in Quality of Life as measured by the EQ-5D-5L Questionnaire [ Time Frame: Baseline, 24 months ]
    Measured by the participant filling out the EQ-5D-5L before surgery and at each experimental visit every 3 months. Each question is scored from 1-5, with 5 having the most difficulty in that area.

Eligibility Criteria

• Ages Eligible for Study: 22 Years to 65 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Male or female age 22-65 at the time of surgery.

• The patient must have one of the following medical conditions:

  • A condition requiring performance of a unilateral transhumeral amputation;
  • An existing transhumeral OPRA device implanted under IDE G150155;
  • An existing unilateral transhumeral amputation; or
  • An existing unilateral transhumeral amputation with previous nerve reinnervation surgery.
• The patient must have a residual humerus of greater than or equal to 10 cm.
• The patient must have a cortical thickness of at least 1.5 mm.
• The patient must have at least a portion of biceps and triceps muscles present.
• The subject must have undergone consultation with at least two upper extremity surgical specialists to ensure they have exhausted all limb salvage options prior to undergoing amputation.
• The patient must have adequate bone stock to support the implanted device.
• In the opinion of the Investigators, normal cognitive function and absence of any physical limitations, addictive diseases or underlying medical conditions that may preclude patient from being a good surgical and/or study candidate.
• Willingness, ability and commitment to participate in baseline and follow-up evaluations for the full length of the study including the prescribed rehabilitation program.
• Written informed consent to participate in the study provided by the patient or legal representative.

Exclusion Criteria:

• Women who are pregnant, lactating, or planning a pregnancy during the first twelve (12) months of the post-surgical follow-up.
• Arthrosis of the ipsilateral glenohumeral joint by radiographs.
• Subjects who have not been completely abstinent from tobacco use for at least 6 weeks preoperatively.
• Active or dormant infection.
• Evidence of or a documented history of severe peripheral vascular disease, diabetes mellitus (type I or type II), skin diseases, neuropathy, neuropathic disease, severe phantom pain, or osteoporosis, such that, in the opinion of the Investigator, the subject will not be a good study candidate.
• History of systemically administered corticosteroids, immunosuppressive therapy, or chemotherapeutic drugs within six (6) months of implant surgery.
• Severe medical co-morbidity, atypical skeletal anatomy, or poor general physical/mental health that, in the opinion of the Investigator, will not allow the subject to be a good study candidate (i.e., other disease processes, other indwelling electronic implants, mental incapacity, substance abuse, shortened life expectancy, and vulnerable patient population).
• Current involvement in another clinical study where that participation may conflict or interfere with the treatment, follow-up or results of this clinical study.

Contacts and Locations

Locations

United States, Michigan

University of Michigan

Ann Arbor, Michigan, United States, 48109

Sponsors and Collaborators

University of Michigan

University of California, San Francisco

More Information

• Responsible Party: Paul Cederna, Robert Oneal Professor of Plastic Surgery, Chief of the Section of Plastic Surgery, University of Michigan
• ClinicalTrials.gov Identifier: NCT03957226
• Other Study ID Numbers: HUM00146699
• First Posted: May 21, 2019
• Last Update Posted: May 13, 2021
• Last Verified: May 2021

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: Yes

Additional relevant MeSH terms:

Neuroma; Nerve Sheath Neoplasms; Neoplasms, Nerve Tissue; Neoplasms by Histologic Type; Neoplasms